DDInter1570 DDInter1115
Chronic angina is a common cardiovascular condition affecting millions worldwide and causes significant disability while interfering with daily activities. Ranolazine is a well-tolerated piperazine derivative used for the management of this condition, offering relief from uncomfortable and debilitating symptoms. With a mechanism of action different from drugs used to treat the same condition, ranolazine is a promising anti-anginal therapy. It was originally approved by the FDA in 2006.
Magnesium citrate is a low volume and osmotic cathartic agent. The cathartic action works primarily through the high osmolarity of the solution which draws large amounts of fluid into space where is used. Magnesium citrate is considered by the FDA as an approved inactive ingredient for approved drug products under the specifications of oral administration of a maximum concentration of 237 mg. It is also considered as an active ingredient in over-the-counter products.
Ranolazine {u} (Compound) resembles {v} (Compound) Eprazinone
Eprazinone {u} (Compound) resembles {v} (Compound) Methadone
Methadone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Magnesium citrate
Ranolazine {u} (Compound) resembles {v} (Compound) Eprazinone
Eprazinone {u} (Compound) resembles {v} (Compound) Dextropropoxyphene
Dextropropoxyphene {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Magnesium citrate
Ranolazine {u} (Compound) resembles {v} (Compound) Carvedilol
Carvedilol {u} (Compound) resembles {v} (Compound) Propafenone
Propafenone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Magnesium citrate
Ranolazine {u} (Compound) resembles {v} (Compound) Carvedilol
Carvedilol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sunitinib
Sunitinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Magnesium citrate
Ranolazine {u} (Compound) resembles {v} (Compound) Carvedilol
Carvedilol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fludrocortisone
Fludrocortisone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Magnesium citrate
Ranolazine {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Clozapine
Clozapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Magnesium citrate
Ranolazine {u} (Compound) upregulates {v} (Gene) DENND2D
DENND2D {u} (Gene) is upregulated by {v} (Compound) Vemurafenib
Vemurafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Magnesium citrate
Ranolazine {u} (Compound) resembles {v} (Compound) Carvedilol
Carvedilol {u} may lead to a major life threatening interaction when taken with {v} Salbutamol
Salbutamol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Magnesium citrate
Ranolazine {u} (Compound) upregulates {v} (Gene) HIST2H2BE
HIST2H2BE {u} (Gene) is downregulated by {v} (Compound) Betamethasone
Betamethasone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Magnesium citrate
Ranolazine {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 3A Inhibitors
Cytochrome P450 3A Inhibitors {u} (Pharmacologic Class) includes {v} (Compound) Lopinavir
Lopinavir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Magnesium citrate
Ranolazine (Compound) resembles Eprazinone (Compound) and Eprazinone (Compound) resembles Methadone (Compound) and Methadone may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Ranolazine (Compound) resembles Eprazinone (Compound) and Eprazinone (Compound) resembles Dextropropoxyphene (Compound) and Dextropropoxyphene may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Ranolazine (Compound) resembles Carvedilol (Compound) and Carvedilol (Compound) resembles Propafenone (Compound) and Propafenone may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Ranolazine (Compound) resembles Carvedilol (Compound) and Carvedilol may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib and Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Ranolazine (Compound) resembles Carvedilol (Compound) and Carvedilol may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Ranolazine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Clozapine (Compound) and Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Ranolazine (Compound) upregulates DENND2D (Gene) and DENND2D (Gene) is upregulated by Vemurafenib (Compound) and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Ranolazine (Compound) resembles Carvedilol (Compound) and Carvedilol may lead to a major life threatening interaction when taken with Salbutamol and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Ranolazine (Compound) upregulates HIST2H2BE (Gene) and HIST2H2BE (Gene) is downregulated by Betamethasone (Compound) and Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Ranolazine (Compound) is included by Cytochrome P450 3A Inhibitors (Pharmacologic Class) and Cytochrome P450 3A Inhibitors (Pharmacologic Class) includes Lopinavir (Compound) and Lopinavir may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate